@CornallLab
Joined September 2018
  • Tweets67
  • Following96
  • Followers91
10Media
Include

Only show posts containing:

Exclude

Hide posts containing:

Time range
-
Minimum likes
Check out our new @SciImmunology paper about the role of DOCK8 in the survival and differentiation of B cells activated by low amounts of antigen: doi.org/10.1126/sciimmunol.a… A big shoutout to @CornallLab & @BetterKidneys Thank you @MRC_TIDU @HumanGeneticsOx @NDMOxford @CAMS_COI_Ox

B cells require DOCK8 to elicit and integrate T cell help when antigen is limiting

B cells activated by low amounts of antigen require DOCK8 to acquire survival and differentiation signals via T cell help.

science.org
4
5
423
B cells activated by low amounts of antigen require DOCK8 to acquire survival and differentiation signals via T cell help @SciImmunology @CornallLab science.org/doi/10.1126/scii…

B cells require DOCK8 to elicit and integrate T cell help when antigen is limiting

B cells activated by low amounts of antigen require DOCK8 to acquire survival and differentiation signals via T cell help.

science.org
11
1
46
3,963
Exciting postdoc role with our friendly supportive group and @trig_oxford @fgissa. Cell therapy for IgA Nephropathy, part of EU /Horizon consortium. Do you like immunology, kidneys and translational research? Informal enquires / DMs for more info welcome my.corehr.com/pls/uoxrecruit…
9
8
1,009
I am really excited to announce that our paper (@PKlenermanLab) exploring MAIT cell transcriptional and TCR repertoire diversity in human blood and liver has been released @NatImmunol nature.com/articles/s41590-0… #MAITcells

Single-cell analysis of human MAIT cell transcriptional, functional and clonal diversity

Nature Immunology - Garner et al. analyzed the single-cell transcriptome and TCR repertoire of matched blood and liver, and resting and activated, human MAIT cells. They identify donor-specific TCR...

nature.com
4
50
5
222
31,925
Researchers at @DavisLab_Oxford investigate the potential of a new combination #immunotherapy of #nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a #CD200R blocker Explore their results in mouse models for colorectal & lung #cancer ➡️bit.ly/3Madlmm
3
1
5
1,719
Very pleased to have my first PhD publication published in @IMTadvances. Using humanised mice we trialled the combination immunotherapy of nivolumab and OX108 (a CD200R blocker) in two tumour models. @DavisLab_Oxford @CornallLab @MRC_HIU @MRC_WIMM @RDMOxford
Immunotherapy Advances Journal@IMTadvances31 Mar 2023
Our latest article explores the potential of a combination #immunotherapy comprising #Nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a CD200R antagonist, in mouse models for colorectal & lung #cancer Explore the results ➡️bit.ly/3nCdUwU
1
5
1
23
3,914
Load more